GLP-1 Is a Schedule Filler Not a Multiplier, and Has Risks

By MRS Allergy · Published

The popularity of GLP-1 for weight loss is well known but its utility as a revenue builder for insurance-based primary care practices is usually overstated. That’s especially true for clinic owners looking to improve the patient experience and the bottom line at the same time. The reimbursement is for clinician time in an office visit, and consequently is just another service to help fill the schedule, and fleetingly at that; it’s not unusually remunerative in any way. Commercial coverage for the service is not the norm, and if anything is shrinking, not growing. Medicare only partially covers costs, and almost no-one is eligible even then, and so far even that limited coverage is temporary. Financially, the bottom line is that even if a clinic could fill its schedule with GLP-1 visits, allergy would still be a far better choice trading the labor hours against reimbursements. And on top of all that, a new warning about potential blindness now attends every prescription. Remote patient monitoring, chronic care management and annual wellness visits are overstated as revenue builders too.

Clinic Revenue From the GLP-1 Weight Loss Is Limited to Office Visits, Limited to Start, and Typically Discontinued in Short Order

At the end of the day, revenues from an added GLP-1 program come from extra office visits, not diagnostics or other codes specific to GLP-1. The pharmacy, not the clinic, gets the drug revenue.

Further, subsequent visits after the initial prescription are not very frequent. Certainly they’re not required. On the contrary, a single office visit is sufficient for payment authorization, and that authorization is good through the December 31, 2027 scheduled end date for the Medicare GLP-1 Bridge program (see below). New authorization is required only if the patient switches drugs. The American Diabetes Association’s 2026 obesity standards call for monthly follow-up for the first three months, quarterly for the rest of the first year, and as little as twice a year after that, or about six visits the first year and two per year thereafter. The subsequent visits after target weight is achieved are for purposes of keeping the weight off. Taken for weight loss, discontinuation when target weight is achieved might be expected except that patients who discontinued semaglutide after only 68 weeks regained about two thirds of the weight. Weight return after discontinuation is consistent with the FDA indication for semaglutide use in weight loss: to “maintain weight reduction long term.”

In reality, office visits also tend to cease before the ADA protocols might suggest. Prime Therapeutics, the BCBS-owned pharmacy benefits manager, found that while continuation statistics have improved markedly since 2021, when about two thirds quit within the first year, over a third of patients placed on GLP-1 for weight loss in early 2024 still discontinued before the end of their first year. Figure 1. If that trend holds, only about one in six will still be visiting the clinic for that purpose at the end of year three, which is double the 8% who started in 2021-22 and were still being treated after three years. In other words, GLP-1 might be thought to be a reason to visit a primary care clinic twice a year long term, but in practice, it simply doesn’t work that way.

Figure 1. Share of obese patients still taking a GLP-1 drug, by time since the first prescription

Share of obese patients still taking a GLP-1 drug, by time since the first prescription Two curves from Prime Therapeutics claims data on commercially insured obese adults without diabetes. Of 5,780 patients who started a GLP-1 drug between January 2021 and March 2022, 32% were still taking one after one year, 15% after two years and 8% after three years. Of 4,992 patients who started Wegovy or Zepbound between January and March 2024, 63% were still taking it after one year. Started any GLP-1 drug, January 2021 to March 2022 (5,780 patients, followed three years) Started Wegovy or Zepbound, January to March 2024 (4,992 patients, followed one year) Still taking the drug 0% 25% 50% 75% 100% Start 6 months 1 year 18 months 2 years 30 months 3 years Time since the first prescription 32% 15% started 2021 to early 2022 8% 63% started early 2024

Commercially insured obese adults without diabetes. A patient counts as still taking the drug until a gap of 60 days or more in supply; in the 2021 to 2022 group, switching to another GLP-1 drug counted as continuing. Source: Prime Therapeutics, “GLP-1 therapy to treat obesity among members without diabetes: three-year persistence,” June 25, 2025, Figures 1 and 2.

Commercial Coverage of GLP-1 Weight Loss Is Not the Norm, and Is Not Growing

Commercially insured patients are often the backbone of a reimbursement-based primary practice, and GLP-1 is not typically covered by commercial payors. It is covered sometimes, however. KFF’s 2026 Employer Health Benefits Survey asked companies with 200 or more workers about their plans with the largest enrollment (companies of 200 or more workers employ 78% of workers who have job-based coverage):

Company size Plan Covers GLP-1 for weight loss
200 to 999 workers 16%
1,000 to 4,999 workers 29%
5,000 or more workers 33%

Because smaller companies are more numerous than larger ones, across all companies with 200 or more workers the figure is 18%. And that coverage often comes with additional conditions such as meeting with a dietician or participation in a lifestyle program, which further reduces coverage as a practical matter. Furthermore, a very large number of adults with employer-provided insurance do not, in fact, work for companies with 200 or more employees, and even fewer small- and micro-employer plans have GLP-1 coverage, further shrinking percentage of adults who have real coverage of GLP-1 for weight loss.

Coverage is not growing overall, and is shrinking in specific instances. Among companies that do not cover GLP-1 weight loss programs, KFF found only 1% say they are very likely to start coverage within a year, compared to 79% say they are not likely, while 12% used to cover it but ceased to in the past year. Those projections are consistent with accounts from patients. KFF’s Health Tracking Poll of GLP-1 use found that among the 18% of adults who have taken a GLP-1 for any reason (weight loss, diabetes, or other rarer conditions), insurance paid the whole cost for 22% and part of it for 48%, and 27% had insurance but paid the whole cost themselves.

GoodRx likewise concluded that “commercial insurance coverage has not improved across the board in 2026” and instead “coverage has become even more restrictive for several popular medications…. the number of people with no commercial insurance coverage for Zepbound increased by 18% compared to 2025….” Only 9% of adults have unrestricted coverage for Wegovy, and less than half of that, only 4%, for Zepbound.

Medicare Covers GLP-1 for Weight Loss for Only 4% of Obese Adults, Coverage Is Only Partial

CMS coverage of GLP-1 drugs for weight loss began in July 2026 with what’s called the Medicare GLP-1 Bridge program. It covers Wegovy, Zepbound and Foundayo for weight reduction for a $50 monthly copay. The program was originally slated to run for only the six months ending at the end of 2026 but was later extended through December 2027.

Eligibility for that program is quite limited, however, both practically and medically. As a practical matter real participation in the program is impacted because of how Medicare counts patient expenditures. The bridge program rules provide that the copay counts toward neither the Part D deductible nor the out-of-pocket-cap. The low income subsidy doesn’t apply either, despite socio-economic demographics associated with obesity.

Medically, most obese adults are not in fact covered. Over 40% of American adults, more than 100 million, qualify as technically obese having a BMI of at least 30. The program is only open to people enrolled in a Medicare drug plan, however, and only a BMI of 35 or more qualifies the enrolled without additional conditions. For lower BMI, comorbidities are required, such as BMI of 27 plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. Other diagnoses are disqualifying, including noncirrhotic MASH, obstructive sleep apnea or type-2 diabetes. KFF, the health-policy research group formerly called the Kaiser Family Foundation, considered all the eligibility factors against prevalence and concluded only 3.8 million American adults qualify for the program, or fewer than 4% of the obese. That’s only 7-8% of Medicare enrollees, estimated from 2023 Medicare claims data.

GLP-1 Weight Loss Is Nowhere Near as Profitable as Allergy Testing

Quantifying those visits monetarily, visits are typically Level IV (99214) while it still qualifies as prescription drug management and the patient remains above target weight. They’re Level III (99213) thereafter. Using the CY2024 averages for claims allowed, to compare apples-to-apples with allergy testing as in Table 1, that’s $119.71 and $85.37 per visit respectively. If a clinic is willing to devote another quarter hour of time for obesity counselling at the rate ascribed to the dedicated code G0447, the average allowed amount for that extra time was $24.74. So, generously and unrealistically assuming 6 visits in the first year, each with counseling as well, and that the patient returns for both visits in the second year, the total average allowed is $1,037.44 for roughly 5½ hours of clinician time.

All things considered, while recent figures suggest the expectation might be too generous, in trading GLP-1 vs. allergy testing as a service line, a clinic might expect 4 to 5 patients out of 100 total patients (not just obese patients) to start GLP-1 each year, realistically resulting in about $9,100 per 100 pts in revenue after three years. That 3yr total revenue per 100 total pts compares to $7,800 for allergy testing (not including allergy treatment) over the same timeframe and denominator.

The deciding factor is that allergy testing revenue is a single visit for a single patient attended by an MA, multiplying the value of a visit, whereas GLP-1 is a schedule filler requiring multiple visits with a practitioner (MD, DO, NP, PA, etc.). Counting a full half hour for an allergy test against 18 minutes for average primary care visit, allergy testing still brings in $560 for each hour of a medical assistant’s time, against $380 for each hour of a clinician’s, whose hour costs something like three to six times as much in salary.

The FDA Now Requires Every GLP-1 to Warn of Vision Loss

A Drug Safety Communication from the FDA on November 9, 2026 requires every GLP-1 maker to add the risk to the Warnings and Precautions section of its label. The order covers the entire class, including Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, and Trulicity, without exception, and it applies regardless of whether the drug is prescribed for diabetes or obesity. The blinding or impairing condition, non-arteritic anterior ischemic optic neuropathy (NAION), is characterized by reduced blood flow to the front of the optic nerve that causes sudden, painless vision loss in one or both eyes, which may be permanent and has no known treatment.